AMLXAmylyx Pharmaceuticals, Inc.

Nasdaq amylyx.com


$ 2.23 $ 0.01 (0.45 %)    

Friday, 23-Aug-2024 15:59:48 EDT
QQQ $ 479.76 $ 5.15 (1.08 %)
DIA $ 411.97 $ 4.35 (1.07 %)
SPY $ 562.00 $ 5.91 (1.06 %)
TLT $ 98.37 $ 0.64 (0.65 %)
GLD $ 231.99 $ 2.65 (1.16 %)
$ 2.23
$ 2.23 x 1,100
$ 2.24 x 1,868
-- - --
$ 1.58 - $ 22.36
340,379
na
151.82M
$ 0.92
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-08-2024 06-30-2024 10-Q
2 05-09-2024 03-31-2024 10-Q
3 02-22-2024 12-31-2023 10-K
4 11-09-2023 09-30-2023 10-Q
5 08-10-2023 06-30-2023 10-Q
6 05-11-2023 03-31-2023 10-Q
7 03-13-2023 12-31-2022 10-K
8 11-10-2022 09-30-2022 10-Q
9 08-11-2022 06-30-2022 10-Q
10 05-12-2022 03-31-2022 10-Q
11 03-31-2022 12-31-2021 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 amylyx-pharmaceuticals-announces-publication-of-data-from-the-phase-2-pegasus-trial-showing-the-effects-of-amx0035-on-cerebrospinal-fluid-biomarkers-of-core-alzheimers-disease-pathology-and-neurodegeneration

- Findings from exploratory analysis of the PEGASUS trial provide preliminary evidence that AMX0035 engages multiple pathologic...

 amylyx-pharma-q2-2024-adj-eps-073-inline

Amylyx Pharma (NASDAQ:AMLX) reported quarterly losses of $(0.73) per share which met the analyst consensus estimate. The compa...

 analyst-ratings-for-amylyx-pharma
Analyst Ratings For Amylyx Pharma
07/12/2024 19:01:19

 goldman-sachs-maintains-neutral-on-amylyx-pharma-raises-price-target-to-4

Goldman Sachs analyst Chris Shibutani maintains Amylyx Pharma (NASDAQ:AMLX) with a Neutral and raises the price target from ...

 why-is-small-cap-amylyx-pharmaceuticals-stock-trading-higher-on-wednesday

Amylyx Pharmaceuticals acquired avexitide from Eiger BioPharmaceuticals Inc. for $35.1 million. Avexitide, a GLP-1 receptor ant...

 hc-wainwright--co-reiterates-buy-on-amylyx-pharma-maintains-8-price-target

HC Wainwright & Co. analyst Andrew Fein reiterates Amylyx Pharma (NASDAQ:AMLX) with a Buy and maintains $8 price target.

Core News & Articles

As part of the transaction, Amylyx assumed certain contractual obligations from Eiger, including a 3% royalty on future sales o...

 amylyx-pharmaceuticals-to-host-conference-call-to-discuss-the-acquisition-of-avexitide-on-wednesday-july-10-2024-at-800-am-et-no-terms-disclosed-in-press-release

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced that Amylyx' managem...

 hc-wainwright--co-reiterates-buy-on-amylyx-pharma-maintains-8-price-target

HC Wainwright & Co. analyst Andrew Fein reiterates Amylyx Pharma (NASDAQ:AMLX) with a Buy and maintains $8 price target.

 mizuho-maintains-neutral-on-amylyx-pharma-lowers-price-target-to-3

Mizuho analyst Graig Suvannavejh maintains Amylyx Pharma (NASDAQ:AMLX) with a Neutral and lowers the price target from $4 to...

 hc-wainwright--co-reiterates-buy-on-amylyx-pharma-maintains-8-price-target

HC Wainwright & Co. analyst Andrew Fein reiterates Amylyx Pharma (NASDAQ:AMLX) with a Buy and maintains $8 price target.

 baird-maintains-neutral-on-amylyx-pharma-lowers-price-target-to-3

Baird analyst Joel Beatty maintains Amylyx Pharma (NASDAQ:AMLX) with a Neutral and lowers the price target from $4 to $3.

 hc-wainwright--co-reiterates-buy-on-amylyx-pharma-maintains-8-price-target

HC Wainwright & Co. analyst Andrew Fein reiterates Amylyx Pharma (NASDAQ:AMLX) with a Buy and maintains $8 price target.

 amylyx-pharmaceuticals-investigational-drug-shows-improved-pancreatic-function-in-patients-with-inherited-disorder

Amylyx's AMX0035 data in treating Wolfram syndrome, with interim data indicating positive effects on diabetes progression, ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION